Singular Genomics Systems, INC Form 4 insider transactions

Kevin Tang, a director and 10% owner of Singular Genomics Systems, Inc., disposed of 372,000 shares of common stock following a merger agreement where shares were converted to $20.00 per share in cash.

Andrew Spaventa, CEO of Singular Genomics Systems, reports the disposal of common stock and derivative securities due to the merger with Singular Genomics Parent, LLC, where shares were converted to $20.00 per share in cash.

Following the merger of Singular Genomics Systems, Inc., CFO Dalen Meeter reports the disposition of common stock and derivative securities, including stock options and restricted stock units, as per the merger agreement.

Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, reports the disposal of shares and derivative securities due to the merger with Singular Genomics Parent, LLC, resulting in a cash payment of $20.00 per share.

Jyotsna Ghai, Chief Operating Officer of Singular Genomics Systems, reports the disposal of shares and stock options due to the merger agreement where the company was acquired for $20.00 per share.

Director Ryan Jason reports the disposition of stock options due to the merger of Singular Genomics Systems, Inc.

Michael J. Pellini, a director at Singular Genomics Systems, reports the disposal of common stock and stock options due to the merger agreement where shares were converted to cash and options were cancelled or converted to cash payments.

Elaine R. Mardis, a director at Singular Genomics Systems, filed a Form 4 disclosing the cancellation of her stock options as a result of the merger agreement with Singular Genomics Parent, LLC.

Director Kim Kamdar reports the disposal of Singular Genomics Systems shares and stock options due to the merger with Singular Genomics Parent, LLC, where shares were converted to cash and options were cancelled or converted to cash payments.

Director Marcia Eisenberg reports the cancellation of stock options due to the merger of Singular Genomics Systems, Inc.

Director David L. Barker reports the disposal of Singular Genomics Systems, Inc. shares and stock options following the merger agreement where shares were converted to cash and options were cancelled or converted to cash payments.

CEO Andrew Spaventa of Singular Genomics Systems, Inc. reports stock transactions including the vesting of restricted stock units, sales to cover tax obligations, and gifts to a living trust.

Dalen Meeter, CFO of Singular Genomics Systems, Inc., reports the acquisition and disposal of company stock and restricted stock units.

Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, reports the acquisition and disposal of common stock and derivative securities.

Jyotsna Ghai, Chief Operating Officer of Singular Genomics Systems, Inc., reports the acquisition of 250 shares of Common Stock through the vesting of Restricted Stock Units.

Jyotsna Ghai, Chief Operating Officer of Singular Genomics Systems, Inc., exercised stock options and acquired shares, including those from vested restricted stock units and an employee stock purchase plan.

Singular Genomics CEO Andrew Spaventa acquired and disposed of company stock following the vesting of restricted stock units, including sales to cover tax obligations and gifts to a living trust.

Singular Genomics' Chief Financial Officer, Dalen Meeter, reported the acquisition of 209 shares of common stock through the settlement of vested Restricted Stock Units and also reported holding 9,002 shares of common stock.

Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, acquired 250 shares of common stock through the vesting of restricted stock units.

Singular Genomics CEO Andrew Spaventa acquired and disposed of shares following the vesting of restricted stock units, including sales to cover tax obligations and gifts to a living trust.

Singular Genomics CFO Dalen Meeter acquired 500 shares of common stock through the settlement of vested Restricted Stock Units (RSUs) on November 9, 2024.

Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, exercised stock options and received 500 shares of common stock on November 9, 2024.

Jyotsna Ghai, Chief Operating Officer of Singular Genomics Systems, Inc., acquired 250 shares of common stock and 250 shares from vested restricted stock units on November 9, 2024.

Jyotsna Ghai, Chief Operating Officer of Singular Genomics Systems, reports the acquisition of 1,666 shares of common stock upon the vesting of Restricted Stock Units.

Kevin Tang, a director and 10% owner of Singular Genomics Systems, has increased his stake in the company through a series of open market purchases.

Chief Financial Officer of Singular Genomics Systems, Dalen Meeter, reports the acquisition and disposal of common stock related to vested Restricted Stock Units.

Eli N. Glezer, Chief Scientific Officer of Singular Genomics Systems, Inc., reports the acquisition of 250 shares of common stock through the settlement of vested Restricted Stock Units.

CEO Andrew Spaventa reports the acquisition and disposal of Singular Genomics Systems, Inc. stock, including transactions related to restricted stock units and a gift transfer.

CEO Andrew Spaventa reports stock transactions including RSU settlements, tax withholdings, and gifts to a living trust, following a reverse stock split.

Jyotsna Ghai, Chief Operating Officer of Singular Genomics Systems, settled vested Restricted Stock Units (RSUs) on August 9, 2024, receiving 250 shares of common stock.